【摘要】 目的 验证再普乐在开放性临床研究中治疗精神分裂症患者的疗效和安全性。方法 对4例大样本再普乐开放性观察性临床试验的数据进行汇总。四项研究使用再普乐的剂量为5～30mg/d，疗程为6周。采用阳性与阴性症状量表(PANSS)以及简明精神病评定量表(BPRS)评定疗效；采用副反应量表(TESS)和Simpson-Angus量表评定不良反应。结果 共2697例患者完成了为期6周的治疗，其中55.8%符合痊愈的标准，30.8%显著进步，9.4%进步，4.0%无变化。再普乐对阳性，阴性和总体精神症状的疗效良好。再普乐治疗发生锥体外系副反应情况少。结论 再普乐在门诊精神分裂症患者治疗中的效果和安全性均较好。

    【关键词】 再普乐；精神分裂症；抗精神病药

    Zyprexa in the treatment of schizophrenia: a open label clinical trial of 2697 schizophrenia patients

    XUE Hai-bo，LIU Ping，ANG Qiu-qing，et al.

    The Shanghai Mental Healthy center，Shanghai 200021，China

    【Abstract】 Objective The purpose of this study was to observe the efficacy and safety of zyprexa in the treatment of schizophreniain daily practical setting.Methods Data from 4 open label observational studies has been collected. Dosage of Zyprexa used in 4 trials was 5～30mg/d， duration of the study was 6 weeks. 2697 schizophrenia patients finished study. The positive and negative syndrome scale (PANSS) and brief psychiatric rating scale (BPRS) were used to assess the clinical efficacy and the abnormal involuntary movement scale (AIMS) ......